New study tracks Maribavir's Real-World success against Post-Transplant CMV
NCT ID NCT06677892
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 75 adults who have had a stem cell or solid organ transplant and are being treated with maribavir for cytomegalovirus (CMV) infection. Researchers will track how well the drug clears the virus, how long treatment lasts, and any side effects. The goal is to see how maribavir works in everyday medical practice under Belgian reimbursement rules.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
maribavir
What this could lead to
If successful, this study could confirm that maribavir is a safe and effective option for treating CMV after transplant in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. CMV recurrence or drug resistance could still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU UCL Namur - site Godinne
RECRUITINGYvoir, 5530, Belgium
Contact
Contact Phone: •••-•••-••••
-
CHU de Liège - site Sart Tilman
RECRUITINGLiège, 4000, Belgium
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cliniques Universitaires Saint-Luc
RECRUITINGBrussels, 1200, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hôpital Erasme
RECRUITINGAnderlecht, 1070, Belgium
Contact
Contact Phone: •••-•••-••••
-
Institut Jules Bordet
RECRUITINGAnderlecht, 1070, Belgium
Contact
Contact Email: •••••@•••••
-
UZA
RECRUITINGEdegem, 2640, Belgium
Contact
Contact Email: •••••@•••••
-
UZBrussel
RECRUITINGJette, 1090, Belgium
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZGent
RECRUITINGGhent, 9000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
UZLeuven
RECRUITINGLeuven, 3000, Belgium
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••